JP2017502006A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502006A5 JP2017502006A5 JP2016539113A JP2016539113A JP2017502006A5 JP 2017502006 A5 JP2017502006 A5 JP 2017502006A5 JP 2016539113 A JP2016539113 A JP 2016539113A JP 2016539113 A JP2016539113 A JP 2016539113A JP 2017502006 A5 JP2017502006 A5 JP 2017502006A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- group
- alkyl
- hydrogen
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 30
- 229910052739 hydrogen Inorganic materials 0.000 claims 25
- 239000001257 hydrogen Substances 0.000 claims 25
- 150000002431 hydrogen Chemical class 0.000 claims 25
- 125000004452 carbocyclyl group Chemical group 0.000 claims 23
- 125000001072 heteroaryl group Chemical group 0.000 claims 22
- 125000000547 substituted alkyl group Chemical group 0.000 claims 22
- 125000003107 substituted aryl group Chemical group 0.000 claims 22
- 239000013078 crystal Substances 0.000 claims 21
- 239000000651 prodrug Substances 0.000 claims 21
- 229940002612 prodrug Drugs 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 21
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 20
- 239000012453 solvate Substances 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 16
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 16
- 125000002252 acyl group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 208000012526 B-cell neoplasm Diseases 0.000 claims 1
- 101100273739 Homo sapiens CD68 gene Proteins 0.000 claims 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000000155 isotopic effect Effects 0.000 claims 1
- 150000002780 morpholines Chemical class 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915684P | 2013-12-13 | 2013-12-13 | |
| US61/915,684 | 2013-12-13 | ||
| US201462036934P | 2014-08-13 | 2014-08-13 | |
| US62/036,934 | 2014-08-13 | ||
| PCT/US2014/070162 WO2015089479A1 (en) | 2013-12-13 | 2014-12-12 | Methods to treat lymphoplasmacytic lymphoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502006A JP2017502006A (ja) | 2017-01-19 |
| JP2017502006A5 true JP2017502006A5 (cg-RX-API-DMAC7.html) | 2018-07-12 |
| JP6879740B2 JP6879740B2 (ja) | 2021-06-02 |
Family
ID=53371894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016539113A Active JP6879740B2 (ja) | 2013-12-13 | 2014-12-12 | リンパ形質細胞性リンパ腫を処置する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | USRE50030E1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3079683A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6879740B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014361798B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2932351A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015089479A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE50030E1 (en) | 2013-12-13 | 2024-07-02 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| WO2015089481A2 (en) | 2013-12-13 | 2015-06-18 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| EP3715346B1 (en) | 2014-10-22 | 2024-01-03 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
| EP3236959B1 (en) | 2014-12-23 | 2025-09-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2016160617A2 (en) | 2015-03-27 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| US10695346B2 (en) | 2015-06-26 | 2020-06-30 | Dana-Farber Cancer Institute, Inc. | 4,6-pyrimidinylene derivatives and uses thereof |
| JP2019507179A (ja) | 2016-03-01 | 2019-03-14 | プロペロン セラピューティックス インコーポレイテッド | Ｗｄｒ５タンパク質−タンパク質結合の阻害剤 |
| WO2017147700A1 (en) | 2016-03-01 | 2017-09-08 | Ontario Institute For Cancer Research (Oicr) | Inhibitors of wdr5 protein-protein binding |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| WO2018049191A1 (en) * | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| WO2018049152A1 (en) * | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| EP3510032B1 (en) | 2016-09-09 | 2022-07-06 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| EP3573618B1 (en) | 2017-01-30 | 2023-08-16 | The Children's Hospital of Philadelphia | Compositions and methods for hemoglobin production |
| US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| CA3079060A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases |
| CA3074381A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| EP3638669A1 (en) | 2017-06-13 | 2020-04-22 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| CN109180677A (zh) * | 2017-06-30 | 2019-01-11 | 厦门大学 | 取代芳基醚类化合物、其制备方法、药用组合物及其应用 |
| CA3070013A1 (en) | 2017-07-18 | 2019-01-24 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| WO2019051199A1 (en) * | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS |
| CA3090275A1 (en) | 2018-02-14 | 2019-08-22 | Dana-Farber Cancer Institute, Inc. | Irak degraders and uses thereof |
| WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
| BR112020016927A2 (pt) | 2018-02-20 | 2020-12-15 | Incyte Corporation | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida e compostos relacionados como inibidores de hpk1 para tratar câncer |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| CN112367991A (zh) | 2018-06-25 | 2021-02-12 | 达纳-法伯癌症研究所股份有限公司 | Taire家族激酶抑制剂及其用途 |
| KR102653681B1 (ko) | 2018-07-31 | 2024-04-03 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제 |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| EP3856348B1 (en) | 2018-09-25 | 2024-01-03 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators |
| TWI721624B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| ES2979163T3 (es) | 2018-10-31 | 2024-09-24 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1 |
| WO2020120257A1 (en) | 2018-12-11 | 2020-06-18 | Bayer Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| EP3902542A4 (en) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| BR112022002059A2 (pt) | 2019-08-06 | 2022-06-07 | Incyte Corp | Formas sólidas de um inibidor de hpk1 |
| WO2021249913A1 (en) | 2020-06-09 | 2021-12-16 | Bayer Aktiengesellschaft | 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer |
| EP4288437A1 (en) | 2021-02-05 | 2023-12-13 | Bayer Aktiengesellschaft | Map4k1 inhibitors |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9816837D0 (en) | 1998-08-04 | 1998-09-30 | Zeneca Ltd | Amide derivatives |
| JP2002512216A (ja) | 1998-04-17 | 2002-04-23 | パーカー ヒューズ インスティテュート | Ｂｔｋインヒビターならびにその同定方法および使用方法 |
| KR20010099609A (ko) | 1998-08-04 | 2001-11-09 | 다비드 에 질레스 | 사이토킨의 생성 억제제로서 유용한 아미드 유도체 |
| IL141979A0 (en) | 1998-09-25 | 2002-03-10 | Astrazeneca Ab | Benzamide derivatives and their use as cytokine inhibitors |
| US6306897B1 (en) | 1999-03-19 | 2001-10-23 | Parker Hughes Institute | Calanolides for inhibiting BTK |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| JP2003509428A (ja) | 1999-09-17 | 2003-03-11 | アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー | 治療薬としてのピラゾロピリミジン |
| US7132438B2 (en) | 2001-10-09 | 2006-11-07 | Amgen Inc. | Benzimidazole derivatives |
| PL375447A1 (en) | 2002-08-14 | 2005-11-28 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| CA2507496C (en) | 2002-12-05 | 2014-11-04 | John D. Shaughnessy | Molecular determinants of myeloma bone disease and uses thereof |
| JP4896518B2 (ja) | 2002-12-13 | 2012-03-14 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | ニコチンアミド系キナーゼ阻害薬 |
| US20070281907A1 (en) | 2003-12-22 | 2007-12-06 | Watkins William J | Kinase Inhibitor Phosphonate Conjugates |
| TW200616974A (en) | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| PE20060664A1 (es) | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
| BRPI0519148A2 (pt) | 2004-12-20 | 2008-12-30 | Sigma Tau Ind Farmaceuti | inibidores de homodimerizaÇço de myd88 |
| WO2006067445A2 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
| AU2005317870A1 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Pyridine carboxamide derivatives for use as anticancer agents |
| CN101106990B (zh) | 2005-01-26 | 2010-12-08 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
| AU2006278627B2 (en) | 2005-08-08 | 2011-08-18 | Janssen Pharmaceutica, N.V. | Thiazolopyrimidine kinase inhibitors |
| US7754717B2 (en) | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| GT200600411A (es) | 2005-09-13 | 2007-05-21 | Novartis Ag | Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular |
| US8101610B2 (en) | 2005-11-14 | 2012-01-24 | Genentech, Inc. | Bisamide inhibitors of hedgehog signaling |
| WO2007071963A2 (en) | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Quinazoline derivatives, process for their preparation and their use as anti-cancer agents |
| WO2007076474A1 (en) * | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases |
| GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
| US20090312396A1 (en) * | 2006-07-10 | 2009-12-17 | Astrazeneca Ab | Methods for cancer treatment using tak1 inhibitors |
| ES2616789T3 (es) | 2006-09-22 | 2017-06-14 | Pharmacyclics, Inc. | Inhibidores de tirosina cinasa de Bruton |
| RS55740B1 (sr) | 2006-10-02 | 2017-07-31 | Squibb & Sons Inc | Humana antitela koja se vezuju za cxcr4 i njihove upotrebe |
| US20120065201A1 (en) | 2007-03-28 | 2012-03-15 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| EA200901377A1 (ru) | 2007-04-17 | 2010-06-30 | Новартис Аг | Соединения из ряда амидов нафталинкарбоновой и изохинолинкарбоновой кислот и их применение |
| WO2008144253A1 (en) | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| TW200906825A (en) | 2007-05-30 | 2009-02-16 | Scripps Research Inst | Inhibitors of protein kinases |
| WO2009017822A2 (en) | 2007-08-02 | 2009-02-05 | Amgen Inc. | Pi3 kinase modulators and methods of use |
| US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| EP2214486A4 (en) * | 2007-10-19 | 2011-03-09 | Avila Therapeutics Inc | HETEROARYL COMPOUNDS AND ITS USES |
| US8067423B2 (en) | 2007-10-23 | 2011-11-29 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib isopropyl alcohol and process for preparation thereof |
| US8394816B2 (en) | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
| WO2009076373A1 (en) | 2007-12-10 | 2009-06-18 | Concert Pharmaceuticals Inc. | Heterocyclic kinase inhibitors |
| JP5529852B2 (ja) | 2008-05-06 | 2014-06-25 | ジリード コネティカット，インコーポレイティド | 置換アミド、その製造法及びＢｔｋインヒビターとしての使用 |
| CA2986640C (en) * | 2008-06-27 | 2019-03-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| US7824861B2 (en) | 2008-07-10 | 2010-11-02 | National Tsing Hua University | Method for quantitative analysis of transcripts with nucleotide polymorphism at specific site |
| BRPI0918021B1 (pt) | 2008-08-13 | 2023-03-14 | Mitsui Chemicals Agro, Inc | Derivados de amida, agente de controle de peste contendo os derivados de amida, e método de controle de pragas |
| MX2011001989A (es) * | 2008-09-02 | 2011-03-30 | Boehringer Ingelheim Int | Nuevas benzamidas, su preparacion y su uso como medicamentos. |
| US8598174B2 (en) | 2008-11-12 | 2013-12-03 | Genetech, Inc. | Pyridazinones, method of making, and method of use thereof |
| SG10201604988YA (en) | 2008-12-23 | 2016-07-28 | Genentech Inc | Methods and compositions for diagnostic use in cancer patients |
| US8809534B2 (en) * | 2009-09-03 | 2014-08-19 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| WO2011029043A1 (en) | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Heteroaryl btk inhibitors |
| CA2784807C (en) | 2009-12-29 | 2021-12-14 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| WO2011095556A1 (en) | 2010-02-08 | 2011-08-11 | N.V. Organon | 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| MX358682B (es) | 2010-07-13 | 2018-08-31 | Hoffmann La Roche | Derivados de pirazolo [1,5a]pirimidina y de tieno[3,2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4). |
| WO2012062704A1 (en) * | 2010-11-09 | 2012-05-18 | Cellzome Limited | Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
| EP2640366A2 (en) | 2010-11-15 | 2013-09-25 | Exelixis, Inc. | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture |
| BR112013029640A2 (pt) | 2011-05-23 | 2017-06-13 | Merck Patent Gmbh | derivados de piridina e pirazina |
| US9073947B2 (en) | 2011-06-10 | 2015-07-07 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity |
| ES2624981T3 (es) | 2011-07-01 | 2017-07-18 | Dana-Farber Cancer Institute, Inc. | Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| PH12014500738A1 (en) | 2011-10-03 | 2014-05-12 | Syngenta Participations Ag | Insecticidal 2-methoxybenzamide derivatives |
| WO2013052699A2 (en) | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
| EP2773639B1 (en) | 2011-11-03 | 2017-04-26 | F. Hoffmann-La Roche AG | Alkylated piperazine compounds as inhibitors of btk activity |
| DK2776032T3 (en) | 2011-11-09 | 2019-02-04 | Bristol Myers Squibb Co | TREATMENT OF HEMATOLOGICAL MALIGNITIES WITH ANTI-CXCR4 ANTIBODY |
| WO2013074986A1 (en) | 2011-11-17 | 2013-05-23 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| AU2012354094C1 (en) | 2011-12-15 | 2015-10-15 | Novartis Ag | Use of inhibitors of the activity or function of PI3K |
| EP2878601B1 (en) | 2012-07-27 | 2018-03-28 | Riken | Agent for treating or controlling recurrence of acute myelogenous leukemia |
| CN103405429A (zh) | 2013-08-22 | 2013-11-27 | 中国药科大学 | 一类vegfr-2抑制剂及其用途 |
| AU2014318614B2 (en) | 2013-09-12 | 2021-01-07 | Dana-Farber Cancer Institute Inc. | Methods for evaluating and treating Waldenstrom's macroglobulinemia |
| WO2015069287A1 (en) | 2013-11-08 | 2015-05-14 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US10612095B2 (en) | 2013-12-06 | 2020-04-07 | Dana-Farber Cancer Institute, Inc. | Methods to distinguish Waldenström's Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance |
| WO2015089481A2 (en) | 2013-12-13 | 2015-06-18 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| USRE50030E1 (en) | 2013-12-13 | 2024-07-02 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| WO2016055982A1 (en) | 2014-10-10 | 2016-04-14 | Acerta Pharma B.V. | Quinoline and quinazoline compounds |
| EP3715346B1 (en) | 2014-10-22 | 2024-01-03 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
| NZ747404A (en) | 2016-03-28 | 2020-03-27 | Presage Biosciences Inc | Pharmaceutical combinations for the treatment of cancer |
| CN109152781A (zh) | 2016-04-29 | 2019-01-04 | 达纳-法伯癌症研究所有限公司 | 作为myd88突变疾病中的治疗靶标的hck |
| CN106008371A (zh) | 2016-06-24 | 2016-10-12 | 谢阳 | 1-芳基脲基环烷基-1-甲酰胺类化合物及其药物组合物和应用 |
| CN106279120A (zh) | 2016-07-15 | 2017-01-04 | 谢阳 | 一种n‑芳基氨基甲酰基脯氨酸类化合物及其药物组合物和应用 |
| CN107056786B (zh) | 2016-10-14 | 2019-05-07 | 苏州明锐医药科技有限公司 | 阿卡替尼的制备方法 |
| EA201992584A1 (ru) | 2017-05-26 | 2020-06-18 | Икнос Сайенсиз Са | Новые ингибиторы map4k1 |
| WO2021071919A1 (en) | 2019-10-08 | 2021-04-15 | Dana-Farber Cancer Institute, Inc. | Hck as a therapeutic target in myd88 mutated diseases |
| AU2020362194A1 (en) | 2019-10-08 | 2022-05-19 | Dana-Farber Cancer Institute, Inc. | A pyrazolopyrimidine derivative as a HCK inhibitor for use in therapy, in particular MYD88 mutated diseases |
-
2014
- 2014-12-12 US US17/534,896 patent/USRE50030E1/en active Active
- 2014-12-12 US US15/104,132 patent/US9856223B2/en not_active Ceased
- 2014-12-12 CA CA2932351A patent/CA2932351A1/en not_active Abandoned
- 2014-12-12 WO PCT/US2014/070162 patent/WO2015089479A1/en not_active Ceased
- 2014-12-12 EP EP14869964.8A patent/EP3079683A4/en not_active Withdrawn
- 2014-12-12 JP JP2016539113A patent/JP6879740B2/ja active Active
- 2014-12-12 AU AU2014361798A patent/AU2014361798B2/en not_active Ceased
-
2017
- 2017-12-19 US US15/847,430 patent/US10633348B2/en active Active